EU Multiple Sclerosis Treatment Market, by Disease (RelapsingRemitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe RelapsingRemitting Multiple Sclerosis (RES)), by Treatment (Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, Symptomatic Therapies), by Drug type (Branded and Generic), by Route of Administration (Oral and Parental), by End User (Hospital, Homecare, Specialty Centers, Others) and by Distribution Channel (Retail Sales and Direct Tender) Growth, Trends and Forecast, 2019-2028
- Published Date: 2022-12-26
- Report ID: 138271
- Pages: 200
-
Format:
Report Overview
The EU Multiple sclerosis treatment market size stood at round USD xx billion in 2019 and is projected to reach USD 0.8 billion by 2028, exhibiting a CAGR of xx% during the forecast period
Multiple sclerosis is a chronic, inflammatory, autoimmune disorder that affects the (CNS) central nervous system, especially the communication between the brain and other areas of the body. Multiple sclerosis (MS) in particular is a demyelinating disease that damages the insulating covers of nerve cells in the brain and spinal cord. There is usually no cure for MS, general care is based on speedy recovery from damage that delays disease progression and manages MS symptoms
Market Drivers
The rising number of patients, increased screening and the need for better care options are thought to be the key factors for the multiple sclerosis treatment market growth during the forecast period. In ageing population, the disease is more prone, hence the surge in the geriatric population further escalates the multiple sclerosis treatment market growth
1. EU Multiple Sclerosis Treatment Market Overview
A. Market Size
2. EU Multiple Sclerosis Treatment Growth Drivers
A. Rising number of patients
B. The surge in the geriatric population
3. EU Multiple Sclerosis Treatment Segmentation.
A. By Disease type
I. RelapsingRemitting Multiple Sclerosis (RRMS)
II. Secondary Progressive Multiple Sclerosis (SPMS)
III. Primary Progressive Multiple Sclerosis (PPMS)
IV. Severe RelapsingRemitting Multiple Sclerosis (RES)
B. By Treatment
I. Preventive Therapies
II. Abortive Therapies
III. Symptomatic Therapies
C. By Route of Administration
I. Oral
II. Parental
D. By End User
I. Hospital
II. Homecare
III. Specialty Centres
IV. Others
E. By Distribution Channel
I. Retail Sales
II. Direct Tender
F. By Drug Type
I. Branded
II. Generic
4. EU Multiple Sclerosis Treatment Major Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles
A. Teva Pharmaceuticals Company overview, Product & Services, Strategies & Financials
B. F. Hoffmann-La Roche Ltd Company overview, Product & Services, Strategies & Financials
C. Pfizer Inc. Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Market Opportunities and Future Trends
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
